These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

584 related items for PubMed ID: 20045290

  • 1. Fluoroquinolone resistance of Pseudomonas aeruginosa isolates causing nosocomial infection is correlated with levofloxacin but not ciprofloxacin use.
    Lee YJ, Liu HY, Lin YC, Sun KL, Chun CL, Hsueh PR.
    Int J Antimicrob Agents; 2010 Mar; 35(3):261-4. PubMed ID: 20045290
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Fluoroquinolone-resistant Pseudomonas aeruginosa in chronic rhinosinusitis.
    Guss J, Abuzeid WM, Doghramji L, Edelstein PH, Chiu AG.
    ORL J Otorhinolaryngol Relat Spec; 2009 Mar; 71(5):263-7. PubMed ID: 19797934
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Characterization of fluoroquinolone and carbapenem susceptibilities in clinical isolates of levofloxacin-resistant Pseudomonas aeruginosa.
    Muramatsu H, Horii T, Takeshita A, Hashimoto H, Maekawa M.
    Chemotherapy; 2005 May; 51(2-3):70-5. PubMed ID: 15870499
    [Abstract] [Full Text] [Related]

  • 6. Predicting hospital rates of fluoroquinolone-resistant Pseudomonas aeruginosa from fluoroquinolone use in US hospitals and their surrounding communities.
    Polk RE, Johnson CK, McClish D, Wenzel RP, Edmond MB.
    Clin Infect Dis; 2004 Aug 15; 39(4):497-503. PubMed ID: 15356812
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Characterization of the onset and consequences of pneumonia due to fluoroquinolone-susceptible or -resistant Pseudomonas aeruginosa.
    Paladino JA, Sunderlin JL, Forrest A, Schentag JJ.
    J Antimicrob Chemother; 2003 Sep 15; 52(3):457-63. PubMed ID: 12888598
    [Abstract] [Full Text] [Related]

  • 9. Pneumonia due to Pseudomonas aeruginosa: the levofloxacin clinical trials experience.
    Tennenberg AM, Davis NB, Wu SC, Kahn J.
    Curr Med Res Opin; 2006 May 15; 22(5):843-50. PubMed ID: 16709306
    [Abstract] [Full Text] [Related]

  • 10. [Susceptibility of 570 Pseudomonas aeruginosa strains to 11 antimicrobial agents and the mechanism of its resistance to fluoroquinolones].
    Lei YC, Wang HB, Sun ZY, Shen ZY.
    Zhonghua Yi Xue Za Zhi; 2003 Mar 10; 83(5):403-7. PubMed ID: 12820918
    [Abstract] [Full Text] [Related]

  • 11. Microbiological rationale for the utilisation of prulifloxacin, a new fluoroquinolone, in the eradication of serious infections caused by Pseudomonas aeruginosa.
    Roveta S, Schito AM, Marchese A, Schito GC.
    Int J Antimicrob Agents; 2005 Nov 10; 26(5):366-72. PubMed ID: 16216467
    [Abstract] [Full Text] [Related]

  • 12. Associations between antibiotic use and changes in susceptibility patterns of Pseudomonas aeruginosa in a private, university-affiliated teaching hospital: an 8-year-experience: 1995-2002.
    Mohr JF, Jones A, Ostrosky-Zeichner L, Wanger A, Tillotson G.
    Int J Antimicrob Agents; 2004 Oct 10; 24(4):346-51. PubMed ID: 15380259
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Analysis of resistance, cross-resistance and antimicrobial combinations for Pseudomonas aeruginosa isolates from 1997 to 2009.
    Master RN, Clark RB, Karlowsky JA, Ramirez J, Bordon JM.
    Int J Antimicrob Agents; 2011 Oct 10; 38(4):291-5. PubMed ID: 21737249
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Comparison of in vitro activities of levofloxacin, ciprofloxacin, ceftazidime, cefepime, imipenem, and piperacillin-tazobactam against aerobic bacterial pathogens from patients with nosocomial infections.
    Huang SS, Lee SC, Lee N, See LC, Tsai MH, Shieh WB.
    J Microbiol Immunol Infect; 2007 Apr 10; 40(2):134-40. PubMed ID: 17446961
    [Abstract] [Full Text] [Related]

  • 17. Antimicrobial usage and resistance trend relationships from the MYSTIC Programme in North America (1999-2001).
    Mutnick AH, Rhomberg PR, Sader HS, Jones RN.
    J Antimicrob Chemother; 2004 Feb 10; 53(2):290-6. PubMed ID: 14711839
    [Abstract] [Full Text] [Related]

  • 18. The impact of fluoroquinolones use on antibiotic resistance in an intensive care burn department.
    Thabet L, Memmi M, Turki A, Messadi AA.
    Tunis Med; 2010 May 10; 88(5):297-300. PubMed ID: 20517823
    [Abstract] [Full Text] [Related]

  • 19. Reduction of fluoroquinolone use is associated with a decrease in methicillin-resistant Staphylococcus aureus and fluoroquinolone-resistant Pseudomonas aeruginosa isolation rates: a 10 year study.
    Lafaurie M, Porcher R, Donay JL, Touratier S, Molina JM.
    J Antimicrob Chemother; 2012 Apr 10; 67(4):1010-5. PubMed ID: 22240401
    [Abstract] [Full Text] [Related]

  • 20. Emergence of high-level fluoroquinolone resistance in emm6 Streptococcus pyogenes and in vitro resistance selection with ciprofloxacin, levofloxacin and moxifloxacin.
    Malhotra-Kumar S, Van Heirstraeten L, Lammens C, Chapelle S, Goossens H.
    J Antimicrob Chemother; 2009 May 10; 63(5):886-94. PubMed ID: 19279051
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.